MENLO PARK, Calif.--(BUSINESS WIRE)-- Geron Corporation (NASDAQ:GERN) today announced that David L. Greenwood, president and chief executive officer, will present an update of the company at 11:30 a.m. ET on Tuesday, February 15, 2011, at the 13th Annual BIO CEO & Investor Conference in New York City.
The webcast for the live audio and slide presentation will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2011/84208505.cfm. The presentation will be archived for replay and available at the same address one hour after conclusion of the live event for a period of 30 days.
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury. For more information, visit www.geron.com.
Anna Krassowska, Ph.D., 650-473-7765
Investor and Media Relations
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Genetics Oncology Pharmaceutical